Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Licenced Physician with a doctoral degree (MD) at Department of Medicine V, University Hospital, LMU Munich | Germany

Dr. med. Laura Lambrecht, born in Munich, is a dedicated physician specializing in pneumology and cardiology with a strong research background in experimental adult cardiology. She completed her medical studies at Ludwig-Maximilians-Universität München and the Technical University of Munich, earning her approbation as a physician. Her doctoral research at the Deutsches Herzzentrum München focused on the functional impact of acetylsalicylic acid on platelet function in carriers of genetic variants in the GUCY1A1 gene, associated with coronary heart disease risk. She actively contributes to clinical work, academic research, and professional leadership roles, while also engaging in cultural and educational initiatives.

Publication Profile 

Orcid

Education 

Dr. Laura Lambrecht earned her Allgemeine Hochschulreife from Max-Bon-Gymnasium Germering with top marks. She began her pre-clinical medical studies at Ludwig-Maximilians-Universität München, achieving “gut” in her first medical examination. She continued her clinical medical studies at the Technical University of Munich, also earning “gut,” and successfully passed her second and third medical examinations. She obtained her approbation as a physician in December. Her doctoral work at the Deutsches Herzzentrum München investigated the effects of acetylsalicylic acid on platelet function in genetically predisposed individuals. She holds certifications in Good Clinical Practice (GCP) and is a member of the Young-DZHK research network.

Experience 

Dr. Lambrecht is currently a physician in training for pneumology at the LMU Klinikum, with a prior rotation in cardiology at the same institution. She has also served as a cardiology trainee at the Medizinisches Versorgungszentrum Dachau, a teaching practice of LMU Munich. Her research experience includes experimental adult cardiology at the Deutsches Herzzentrum München in the group of Prof. Dr. H. Schunkert. She has held leadership roles such as assistant representative at the LMU Klinikum. Alongside her clinical career, she has been actively involved in student representation, faculty governance, and medical community engagement through various institutional committees and organizations.

Awards and Honors 

Dr. Lambrecht’s academic achievements include graduating from Max-Bon-Gymnasium Germering with “sehr gut” and consistently strong performance in her medical studies at LMU and TU Munich. She earned her approbation as a physician and secured a place in the prestigious Young-DZHK network, reflecting her recognized potential in cardiovascular research. She received funding for her doctoral project examining the genetic and pharmacological interplay in coronary heart disease. Her leadership as assistant representative and elected student council member also reflects peer recognition. Her commitment to academic excellence, research innovation, and community service positions her as a promising contributor to both clinical and research fields.

Research Focus 

Dr. Lambrecht’s primary research interest lies in cardiovascular pharmacogenetics, particularly the influence of genetic variants on drug response. Her doctoral project focused on the functional effects of acetylsalicylic acid on platelet function in carriers of genetic variants in the coronary heart disease risk gene GUCY1A1. She is interested in translating molecular findings into personalized therapeutic strategies for cardiovascular patients. Her work integrates clinical cardiology with laboratory-based functional assays to better understand genotype-specific treatment responses. Additionally, she engages in interdisciplinary collaboration between cardiology and pneumology, aiming to address comorbid conditions and improve patient care through evidence-based, precision medicine approaches.

Publication Top Notes

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.

Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Chair Professor at Shanghai Jiao Tong University School of Medicine | China

Prof. Song Guo Zheng, M.D., Ph.D., is an internationally renowned immunologist and clinician-scientist specializing in rheumatology, molecular immunology, and translational medicine. He currently serves as Chair Professor and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University. With academic leadership roles across prestigious institutions in the U.S. and China, his pioneering work spans autoimmunity, cell therapy, and immunoregulation. A prolific author with over 110 peer-reviewed publications in top-tier journals, Prof. Zheng is also a highly decorated researcher and active leader in global immunology societies. His contributions continue to shape modern immunotherapy and precision medicine.

Publication Profile 

Google Scholar

Orcid

Education 

Prof. Zheng earned his Ph.D. in Molecular Immunology from the University of Orleans, France (2011), and a Master’s in Pathology and Immunology from Shanghai Medical University (1992). He completed his M.D. at Anhui Medical University (1984). His clinical training included a residency in surgery at Chizhou City Hospital (1984–1989) and an internship at Shanghai Zhabei Hospital (1983–1984). He further pursued a pathology fellowship at Shanghai Medical University Cancer Hospital (1989–1993). These academic and clinical foundations laid the groundwork for a distinguished career in immunology, clinical research, and translational medicine across both China and the United States.

Experience 

Prof. Zheng currently serves as Chair Professor at Shanghai Jiao Tong University and Dean of the School of Cell and Gene Therapy (2023–Present). He previously held senior positions including the Ronald L. Whisler Chair in Rheumatology and Immunology at Ohio State University (2018–2022) and Director at Penn State University’s College of Medicine (2013–2018). His U.S. academic journey began at the University of Southern California as an assistant and associate professor (2004–2013), after postdoctoral work at USC and UCLA. With leadership in research, teaching, and clinical science, he has become a global authority in immunological therapeutics and rheumatology.

Awards

Prof. Zheng has received numerous prestigious honors, including the Outstanding Scientist Award (2023, USA) and the Distinguished Clinical Immunologist Award (2019, China). He was awarded the Edmund L. Dubois Award (2019), NIH STAR Award (2016–2021), and was Chair of NIH MOSS Study Section (2016). Notably, he earned the James R. Klinenberg Award for best immunologist in Southern California (2007) and the Freda Newton Memorial Scholar Award (2006). He is an elected member of The Henry Kunkel Society (2012) and a recipient of the ACR Investigator Award (2008–2010), reflecting his impactful and sustained contributions to clinical immunology.

Research Focus 

Prof. Zheng’s research centers on molecular immunology, particularly in autoimmune diseases, Treg/Th17 cell modulation, and immune tolerance mechanisms. He investigates immunometabolism, gene and cell therapy, and inflammatory signaling pathways with an emphasis on clinical translation. His studies on cytokines, nanomedicine, and immune checkpoint regulation aim to advance precision therapeutics for rheumatic and inflammatory diseases. He integrates cutting-edge techniques including single-cell sequencing, CRISPR-based modulation, and nano-drug delivery systems. His innovative research is highly cited and supports next-generation treatments for autoimmunity, cancer immunotherapy, and organ-specific inflammation, shaping global trends in immune-based medical interventions.

Publication Top Notes

Natural and induced CD4+ CD25+ cells educate CD4+ CD25− cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10

IL-2 is essential for TGF-β to convert naive CD4+ CD25− cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells

Role of vitamin A in the immune system

Generation ex vivo of TGF-β-producing regulatory T cells from CD4+ CD25− precursors

Vitamin D and chronic diseases

TGF-β requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+ CD25+ regulatory cells

Natural and TGF-β–induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other

Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications

Cutting edge: Foxp3+ CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6

Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms

The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3

The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets

Conclusion

Given his outstanding scientific productivity, leadership in global immunology communities, and groundbreaking research on immune regulation, Prof. Song Guo Zheng is highly suitable for the Best Researcher Award. His body of work demonstrates not only scientific depth and innovation but also sustained impact on the field of immunology and clinical medicine. With ongoing contributions and strategic improvements, he remains a central figure in advancing immune-based therapies and education worldwide.